Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
3.740
+0.535 (16.69%)
At close: Nov 4, 2024, 4:00 PM
3.690
-0.050 (-1.34%)
After-hours: Nov 4, 2024, 4:47 PM EST
Cardiff Oncology Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cardiff Oncology stock have an average target of 9.67, with a low estimate of 7.00 and a high estimate of 14. The average target predicts an increase of 158.56% from the current stock price of 3.74.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 6, 2024.
Analyst Ratings
The average analyst rating for CRDF stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +113.90% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +274.33% | May 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $14 | Strong Buy | Maintains | $12 → $14 | +274.33% | Mar 6, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $5 → $7 | Buy | Maintains | $5 → $7 | +87.17% | Mar 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $12 | Strong Buy | Maintains | $13 → $12 | +220.86% | Aug 11, 2023 |
Financial Forecast
Revenue This Year
540.80K
from 488.00K
Increased by 10.82%
Revenue Next Year
328.44K
from 540.80K
Decreased by -39.27%
EPS This Year
-1.02
from -0.93
EPS Next Year
-1.06
from -1.02
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 822,150 | 1.1M | 420,000 | ||
| Avg | 540,804 | 328,440 | 135,997 | ||
| Low | 392,000 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 68.5% | 96.2% | 27.9% | ||
| Avg | 10.8% | -39.3% | -58.6% | ||
| Low | -19.7% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.96 | -0.84 | -1.21 | ||
| Avg | -1.02 | -1.06 | -1.35 | ||
| Low | -1.04 | -1.17 | -1.48 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.